Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Area of Science:

• Molecular Biology
• Pharmacology
• Gene Regulation

Background:

• Antisense oligonucleotides (ASOs) are short nucleic acid sequences designed to modulate gene expression within living cells.
• ASOs can influence fundamental cellular processes including function, division, and responses to various stimuli.
• Despite preclinical and clinical progress, ASOs are not yet established as mainstream therapeutics.

Purpose of the Study:

• To review the current status of antisense oligonucleotide therapeutics.
• To identify key challenges impeding the clinical success of ASO drugs.
• To explore how insights from ASO development can inform other oligonucleotide-based therapeutic strategies.

Main Methods:

• Literature review of preclinical and clinical studies on antisense oligonucleotides.
• Analysis of challenges in ASO drug development, including efficacy, off-target effects, delivery, and safety.
• Comparative analysis with emerging oligonucleotide therapeutic modalities.

Main Results:

• ASOs demonstrate potential in regulating gene expression and cellular functions.
• Significant obstacles remain, including suboptimal efficacy, unintended gene silencing (off-target effects), challenges in drug delivery to target tissues, and adverse side effects.
• The development of ASOs has provided valuable insights applicable to other nucleic acid-based therapies.

Conclusions:

• Antisense oligonucleotide therapeutics show promise but require overcoming substantial challenges for widespread clinical adoption.
• Addressing issues of efficacy, specificity, delivery, and safety is crucial for advancing ASO-based medicines.
• Knowledge gained from antisense drug development is transferable and beneficial for the advancement of related oligonucleotide therapeutics, such as RNA interference (RNAi) and microRNA (miRNA) therapies.